COCH

Second of Four Planned Modules Moves Rolling FDA Review ForwardAdvances Toward Targeted Completion of the Final Clinical Module Submission in Q2 2027White Bear Lake, Minnesota--(Newsfile Corp. - October 12, 2026) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health and neuroprosthetics company pioneering fully implanted hearing solutions, today announced the submission of the second module of its Modular Premarket Approval ("PMA") application to the U.S. Food and Drug Administration ("FDA") for the Acclaim® cochlear implant, which has received FDA Breakthrough Device Designation.The second module, which included primarily engineering information, follows t

8-K - Envoy Medical, Inc. (0001840877) (Filer)

Lake Street initiated coverage of Envoy Medical with a rating of Buy and set a new price target of $2.50

Canadian and Hong Kong Patents Continue to Strengthen Intellectual Property Protection Across Envoy Medical's Fully Implanted Hearing PlatformWhite Bear Lake, Minnesota--(Newsfile Corp. - September 22, 2026) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the grant of two additional international patents, expanding its global intellectual property portfolio to 97 patents, consisting of 40 U.S. and 57 foreign patents. In addition, the Company has 26 pending foreign applications and 9 pending U.S. applications. "As a company known for fully implanted hearing devices that leverage the

DEFA14A - Envoy Medical, Inc. (0001840877) (Filer)

White Bear Lake, Minnesota--(Newsfile Corp. - September 2, 2026) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced that Brent Lucas, Envoy Medical's Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference, on September 14-16, 2026 at the Lotte New York Palace Hotel in New York City.H.C. Wainwright Conference Presentation Details:Presentation Date: Tuesday, September 15, 2026Presentation Time: 2:00 PM ETLocation: Kennedy II Room, Lotte New York Palace Hotel, New York, NYWebcast Link: https://ir.envoymedical.com/news-events/ir-calendar

DEF 14A - Envoy Medical, Inc. (0001840877) (Filer)

8-K - Envoy Medical, Inc. (0001840877) (Filer)

4 - Envoy Medical, Inc. (0001840877) (Issuer)

PRE 14A - Envoy Medical, Inc. (0001840877) (Filer)

8-K - Envoy Medical, Inc. (0001840877) (Filer)

10-Q - Envoy Medical, Inc. (0001840877) (Filer)

Submitted First Module of Modular PMA Application to FDASubsequent to Quarter End, the Company Reported Positive 12-Month Stage 1 Data Showing Continued Improvement in Speech Perception White Bear Lake, Minnesota--(Newsfile Corp. - August 10, 2026) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today reported financial results for the second quarter ended June 30, 2026, and provided a business update, highlighting continued execution on its corporate initiatives."The second quarter moved us measurably closer to bringing our fully implanted cochlear implant to market," said Brent Lucas, Chief Execu

White Bear Lake, Minnesota--(Newsfile Corp. - July 21, 2026) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that it has surpassed the three-month milestone for all 56 patients enrolled in the Company's pivotal clinical trial evaluating the investigational fully implanted Acclaim® cochlear implant. This marks another important clinical trial milestone as the Company continues to build momentum with the hearing industry."Envoy Medical continues to demonstrate its ability to execute," said Brent Lucas, Chief Executive Officer of Envoy Medical. "Each milestone achieved brings us one bi

Mean CNC word recognition scores for Stage 1 cohort improved to 53.2% at 12 months from 15.2% pre-implantation, a 38.0 percentage point gain that continued to build on the 24.0 percentage point improvement reported at 6 monthsWhite Bear Lake, Minnesota--(Newsfile Corp. - July 14, 2026) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced positive 12-month data from the first 10 participants in Stage 1 of its pivotal clinical trial evaluating the investigational fully implanted Acclaim® cochlear implant.The Stage 1 cohort demonstrated a mean Consonant-Nucleus-Consonant ("CNC") word recogn

8-K - Envoy Medical, Inc. (0001840877) (Filer)

Modular Regulatory Strategy Creates Defined Milestone Cadence, Enables Earlier FDA Engagement, and Supports Targeted Final Clinical Module Submission Planned for Q2 2027White Bear Lake, Minnesota--(Newsfile Corp. - June 30, 2026) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the submission of the first module of its Modular Premarket Approval ("PMA") application to the U.S. Food and Drug Administration ("FDA") for its FDA Breakthrough Device-designated product.The submission marks the first regulatory milestone in the Company's planned modular PMA strategy. Unlike a traditional PM

NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the June 24th & 25th Life Sciences Virtual Investor Forum are now available for on-demand viewing. REGISTER AND VIEW PRESENTATIONS HERE Select companies are accepting 1x1 management meeting requests through June 19th. Please Schedule 1x1 Meetings here. The presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company’s resource section. Presenting Companies CompanyTicker(s)MetaVia Inc.(NASDAQ:MTVA)Nasus Pharma Ltd.(NYSE:NSRX)CytoSorbents Corporation(NASD

8-K - Envoy Medical, Inc. (0001840877) (Filer)

Termination Reflects Company's Confidence in Current Capital PositionWhite Bear Lake, Minnesota--(Newsfile Corp. - June 25, 2026) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a hearing health company pioneering fully implanted hearing solutions, today announced that it has formally terminated its at-the-market equity facility (the "ATM Facility").The ATM Facility, under which the Company was previously authorized to offer and sell up to $15 million worth of shares of its common stock from time to time, has been terminated effective June 24, 2026.To be added to the Envoy Medical email distribution list, please email Envoy@kcsa.com with COCH in the subject line.About Envoy Medical,

4 - Envoy Medical, Inc. (0001840877) (Issuer)

NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place June 24th & 25th, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here. "This week's Life Sciences Virtual Investor Forum brings

White Bear Lake, Minnesota--(Newsfile Corp. - June 18, 2026) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that Brent Lucas, CEO of Envoy Medical, will present at the Virtual Life Sciences Investor Forum and the Biotech Webull Webinar Panel on June 25, 2026.Life Sciences Virtual Investor ForumDates: June 24th & 25thPresentation Day and Time: Thursday, June 25, 2026, at 1:00 p.m. ETWebcast Link Biotech Webull Webinar PanelPresentation Day and Time: Thursday, June 25, 2026, at 2:40 p.m. ETWebcast LinkTo schedule a meeting with the Envoy Medicals management team, please contact KCSA

EFFECT - Envoy Medical, Inc. (0001840877) (Filer)

POS AM - Envoy Medical, Inc. (0001840877) (Filer)